click below
click below
Normal Size Small Size show me how
Oncology PCOL
Exam 1
| Drug | Class | MOA | Target(s) | ADRs |
|---|---|---|---|---|
| Gefitinib | TK Inhibitor - EGFR Antagonist | Reversible inhibitor of EGFR | EGFR | Secondary resistance, Liver function effects, Interstitial lung disease |
| Lapatinib | TK Inhibitor - EGFR Antagonist | Reversible inhibitor of EGFR + HER-2 | EGFR + HER2 | BW for Hepatotoxicity |
| Tucatinib | TK Inhibitor - EGFR Antagonist | Reversible HER-2 inhibitor | HER2 | Diarrhea + Hepatotoxicity |
| Afatinib | TK Inhibitor - EGFR Antagonist | Irreversible inhibitor of EGFR + HER2 + HER4 | EGFR + HER2 + HER4 | |
| Osimertinib | TK Inhibitor - EGFR Antagonist | Irreversible EGFR inhibitor (including for variants L858R + exon 19 deletion) | EGFR | Interstitial lung disease, Pneumonia, Pulmonary embolism |
| Cetuximab | TK Inhibitor - EGFR Antagonist | High specificity Chimeric mouse/human IgG1 against EGFR (must evaluate for KRAS) | EGFR | Rash = Tumor response BW for Infusion reactions + Cardiopulmonary arrest |
| Panitumumab | TK Inhibitor - EGFR Antagonist | Human kappa monoclonal antibody against EGFR | EGFR | BW for dermatologic reactions |
| Trastuzumab | TK Inhibitor - EGFR Antagonist | Humanized monoclonal antibody against HER2; Downregulates HER2 and induces antibody-dependent cellular cytotoxicity | HER2 | BW for Cardiomyopathy, Infusion reactions, Pulmonary toxicity, Embryo-fetal toxicity *DI with Warfarin |
| Ado-trastuzumab emtansine | TK Inhibitor - EGFR Antagonist | Trastuzumab linked to small molecule cytotoxin (DM1) which binds to HER2 and is released to interrupt the cell cycle and causes apoptosis | HER2 | BW for Hepatotoxicity, Cardiotoxicity, Embryo-fetal toxicity |
| fam-trastuzumab deruxtecan-nxki | TK Inhibitor - EGFR Antagonist | Trastuzumab attached to Dxd (topoisomerase I inhibitor) which is released and causes DNA damage/apoptosis | HER2 | BW for Interstitial lung disease, Embryo-fetal toxicity |
| Pertuzumab | TK Inhibitor - EGFR Antagonist | Humanized monoclonal antibody targeting EHR2 *Used with trastuzumab to target different regions on HER2 receptor | HER2 | BW for Left ventricular dysfunction and Embryo-fetal toxicity |
| Crizotinib | TK Inhibitor - ALK Inhibitor | Binds to intracellular ALK, preventing phosphorylation | ALK + ROS1 + MET | Secondary resistance, Interstitial lung disease, Hepatotoxicity, QT prolongation, Bradycardia |
| Alectinib | TK Inhibitor - ALK Inhibitor | 2nd gen ALK inhibitor (better BBB penetration) | ALK + RET | Visual disturbances, Photo sensitivity, Fetal harm |
| Brigatinib | TK Inhibitor - ALK Inhibitor | 2nd gen ALK inhibitor (better BBB penetration) | ALK + ROS1 + FLT3 + EGFR Variants | Visual disturbances, Photo sensitivity, Fetal harm |
| Ensartinib | TK Inhibitor - ALK Inhibitor | 2nd gen ALK inhibitor (better BBB penetration) | ALK + ROS1 + MET | Visual disturbances, Photo sensitivity, Fetal harm |
| Lorlatinib | TK Inhibitor - ALK Inhibitor | 3rd gen ALK inhibitor (efficacious against ALK-resistant mutations) | ALK + ROS1 | Fetal harm |
| Midostaurin | TK Inhibitor - FLT3 Inhibitor | Inhibits FLT3, including ITD and TKD variants | FLT3 | Fetal harm |
| Quizartinib | TK Inhibitor - FLT3 Inhibitor | Inhibits FLT3, more potent for ITD | FLT3 | BW for QT prolongation, TdP and Cardiac arrest *CI in hypokalemia, hypomagnesemia, long QT |
| Entrectinib | TK Inhibitor - TRK Inhibitor | Inhibitor of TRKs, ROS1, ALK kinases | TRK + ROS1 + ALK | |
| Larotrectinib | TK Inhibitor - TRK Inhibitor | Inhibitor of TRK kinases | TRK | Neurotoxicity, Hepatotoxicity |
| Repotrectinib | TK Inhibitor - TRK Inhibitor | 2nd gen inhibitor of TRKs and ROS2 (better efficacy) | TRK + ROS1 | |
| Pralsetinib | TK Inhibitor - RET Inhibitor | Inhibits RET | RET | |
| Selpercatinib | TK Inhibitor - RET Inhibitor | Inhibits RET, plus VEGFR and FGFRs | RET + VEGFR + FGFR | Impaired wound healing, Hepatotoxicity, QTc prolongation |
| Amivantamab-vmjw | TK Inhibitor - MET Inhibitor | Bispecific antibody that targets EGFR and MET; Stops signaling from receptors and kills targeted cells by antibody-dependent cellular cytotoxicity | MET + EGFR | Fetal harm |
| Capmantinib | TK Inhibitor - MET Inhibitor | MET Kinase inhibitor | MET | Peripheral edema |
| Tepotinib | TK Inhibitor - MET Inhibitor | MET Kinase inhibitor | MET | Peripheral edema |
| Acalabrutinib | TK Inhibitor - BTK Inhibitor | 2nd gen Irreversible BTK inhibitor (less CV effects) | BTK | Myelosuppression, Hemorrhaging **Better ADR profile than Zanubrutinib |
| Zanubrutinib | TK Inhibitor - BTK Inhibitor | 2nd gen Irreversible BTK inhibitor (less CV effects) | BTK | Myelosuppression, Hemorrhaging |